^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TQB3804
i
Other names: TQB3804, TQB-3804, TQB 3804
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
EGFR inhibitor
Related drugs:
3years
.EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. (PubMed, Pharmacol Res)
EGFR mutations, such as T790M and C797S, are the most common mechanism of EGFR-TKI resistance. Here, we discuss the mechanisms of EGFR-TKIs resistance induced by secondary EGFR mutations, highlight the development of targeted drugs to overcome EGFR mutation-mediated resistance, and predict the promising directions for development of novel candidates.
Clinical • Review • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR C797S
|
Tagrisso (osimertinib) • Ameile (aumolertinib) • Pozenveo (poziotinib) • Ivesa (furmonertinib) • Exkivity (mobocertinib) • zipalertinib (CLN-081) • TQB3804
Share via
